Lumos Diagnostics Holdings (ASX:LDX) has gained Medicare reimbursement for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor (MAC) CGS Administrators, at a rate of $41.38 per test, effective May 1, according to a Tuesday filing with the Australian bourse.
The company has now achieved coverage from six of seven MACs, the filing said.